Drug-transporter proteins in clinical multidrug resistance

R. J. Scheper, H. J. Broxterman, G. L. Scheffer, C. J L M Meijer, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

Upon exposure to chemotherapeutic drugs, mammalian cells can acquire resistance to structurally and functionally unrelated compounds, a property known as multidrug resistance (MDR). One MDR mechanism, i.e. by the overexpression of a plasma membrane protein, P-glycoprotein (P-gp), has been identified at the molecular level. The mdr1 gene-encoded P-gp acts as a drug efflux pump, lowering intracellular drug concentration by active extrusion of drugs from the cell. The role of P-gp in determining clinical resistance to multiple anticancer drugs is likely to be largely different for various tumor types. Recently we selected a monoclonal antibody (mAb LRP56) for strong, granular cytoplasmic reactivity with MDR tumor cell lines without P-gp (over)expression. None or weak reactivity was observed with parental and P-gp positive cell lines. We hypothesize that as yet-undefined drug transport-mediating proteins are inserted in intracellular membranes lining the exocytotic compartment and thus may contribute to clinical multidrug resistance.

Original languageEnglish (US)
Pages (from-to)25-32
Number of pages8
JournalClinica Chimica Acta
Volume206
Issue number1-2
DOIs
StatePublished - Mar 13 1992
Externally publishedYes

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Pharmaceutical Preparations
Proteins
Cells
Tumors
Intracellular Membranes
Cell membranes
Tumor Cell Line
Linings
Extrusion
Blood Proteins
Carrier Proteins
Membrane Proteins
Genes
Monoclonal Antibodies
Cell Membrane
Pumps
Membranes
Cell Line

Keywords

  • Exocytosis
  • Multidrug-resistance
  • P-glycoprotein
  • Transporter proteins

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Meijer, C. J. L. M., & Pinedo, H. M. (1992). Drug-transporter proteins in clinical multidrug resistance. Clinica Chimica Acta, 206(1-2), 25-32. https://doi.org/10.1016/0009-8981(92)90005-B

Drug-transporter proteins in clinical multidrug resistance. / Scheper, R. J.; Broxterman, H. J.; Scheffer, G. L.; Meijer, C. J L M; Pinedo, H. M.

In: Clinica Chimica Acta, Vol. 206, No. 1-2, 13.03.1992, p. 25-32.

Research output: Contribution to journalArticle

Scheper, RJ, Broxterman, HJ, Scheffer, GL, Meijer, CJLM & Pinedo, HM 1992, 'Drug-transporter proteins in clinical multidrug resistance', Clinica Chimica Acta, vol. 206, no. 1-2, pp. 25-32. https://doi.org/10.1016/0009-8981(92)90005-B
Scheper RJ, Broxterman HJ, Scheffer GL, Meijer CJLM, Pinedo HM. Drug-transporter proteins in clinical multidrug resistance. Clinica Chimica Acta. 1992 Mar 13;206(1-2):25-32. https://doi.org/10.1016/0009-8981(92)90005-B
Scheper, R. J. ; Broxterman, H. J. ; Scheffer, G. L. ; Meijer, C. J L M ; Pinedo, H. M. / Drug-transporter proteins in clinical multidrug resistance. In: Clinica Chimica Acta. 1992 ; Vol. 206, No. 1-2. pp. 25-32.
@article{17cdfadb3e01436b815576e9ddc3f9c1,
title = "Drug-transporter proteins in clinical multidrug resistance",
abstract = "Upon exposure to chemotherapeutic drugs, mammalian cells can acquire resistance to structurally and functionally unrelated compounds, a property known as multidrug resistance (MDR). One MDR mechanism, i.e. by the overexpression of a plasma membrane protein, P-glycoprotein (P-gp), has been identified at the molecular level. The mdr1 gene-encoded P-gp acts as a drug efflux pump, lowering intracellular drug concentration by active extrusion of drugs from the cell. The role of P-gp in determining clinical resistance to multiple anticancer drugs is likely to be largely different for various tumor types. Recently we selected a monoclonal antibody (mAb LRP56) for strong, granular cytoplasmic reactivity with MDR tumor cell lines without P-gp (over)expression. None or weak reactivity was observed with parental and P-gp positive cell lines. We hypothesize that as yet-undefined drug transport-mediating proteins are inserted in intracellular membranes lining the exocytotic compartment and thus may contribute to clinical multidrug resistance.",
keywords = "Exocytosis, Multidrug-resistance, P-glycoprotein, Transporter proteins",
author = "Scheper, {R. J.} and Broxterman, {H. J.} and Scheffer, {G. L.} and Meijer, {C. J L M} and Pinedo, {H. M.}",
year = "1992",
month = "3",
day = "13",
doi = "10.1016/0009-8981(92)90005-B",
language = "English (US)",
volume = "206",
pages = "25--32",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Drug-transporter proteins in clinical multidrug resistance

AU - Scheper, R. J.

AU - Broxterman, H. J.

AU - Scheffer, G. L.

AU - Meijer, C. J L M

AU - Pinedo, H. M.

PY - 1992/3/13

Y1 - 1992/3/13

N2 - Upon exposure to chemotherapeutic drugs, mammalian cells can acquire resistance to structurally and functionally unrelated compounds, a property known as multidrug resistance (MDR). One MDR mechanism, i.e. by the overexpression of a plasma membrane protein, P-glycoprotein (P-gp), has been identified at the molecular level. The mdr1 gene-encoded P-gp acts as a drug efflux pump, lowering intracellular drug concentration by active extrusion of drugs from the cell. The role of P-gp in determining clinical resistance to multiple anticancer drugs is likely to be largely different for various tumor types. Recently we selected a monoclonal antibody (mAb LRP56) for strong, granular cytoplasmic reactivity with MDR tumor cell lines without P-gp (over)expression. None or weak reactivity was observed with parental and P-gp positive cell lines. We hypothesize that as yet-undefined drug transport-mediating proteins are inserted in intracellular membranes lining the exocytotic compartment and thus may contribute to clinical multidrug resistance.

AB - Upon exposure to chemotherapeutic drugs, mammalian cells can acquire resistance to structurally and functionally unrelated compounds, a property known as multidrug resistance (MDR). One MDR mechanism, i.e. by the overexpression of a plasma membrane protein, P-glycoprotein (P-gp), has been identified at the molecular level. The mdr1 gene-encoded P-gp acts as a drug efflux pump, lowering intracellular drug concentration by active extrusion of drugs from the cell. The role of P-gp in determining clinical resistance to multiple anticancer drugs is likely to be largely different for various tumor types. Recently we selected a monoclonal antibody (mAb LRP56) for strong, granular cytoplasmic reactivity with MDR tumor cell lines without P-gp (over)expression. None or weak reactivity was observed with parental and P-gp positive cell lines. We hypothesize that as yet-undefined drug transport-mediating proteins are inserted in intracellular membranes lining the exocytotic compartment and thus may contribute to clinical multidrug resistance.

KW - Exocytosis

KW - Multidrug-resistance

KW - P-glycoprotein

KW - Transporter proteins

UR - http://www.scopus.com/inward/record.url?scp=0026566377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026566377&partnerID=8YFLogxK

U2 - 10.1016/0009-8981(92)90005-B

DO - 10.1016/0009-8981(92)90005-B

M3 - Article

C2 - 1349270

AN - SCOPUS:0026566377

VL - 206

SP - 25

EP - 32

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -